We have a diversified and balanced portfolio covering multiple therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.

The company also has a vaccine platform discovering and developing glycoconjugate vaccines containing synthetic antigenic glycan molecules with and without a carrier protein to prevent infection.

         

Compound

Mechanism of action

Target indication

Status

More Information

QUVIVIQ™   (daridorexant)

Dual orexin receptor antagonist

Insomnia

Commercially available in the US, Germany, Italy, Switzerland, Spain, and the UK;
approved in the EU and Canada;
Phase 2 in pediatric insomnia – recruiting

Investor webcast

Aprocitentan

Dual endothelin receptor antagonist

Difficult-to-control (resistant) hypertension

NDA under review in the US, MAA under review in the EU, other filings in preparation

Investor webcast

Lucerastat

Glucosylceramide synthase inhibitor

Fabry disease

Phase 3 primary endpoint not met, Open Label Extension study (OLE) ongoing

 

Selatogrel

P2Y12 inhibitor

Suspected acute myocardial infarction

Phase 3 recruiting

Investor webcast

Cenerimod

S1P1 receptor modulator

Systemic lupus erythematosus

Phase 3 recruiting

Investor webcast

ACT-1004-1239

ACKR3 / CXCR7 antagonist

Multiple sclerosis and other demyelinating diseases

Phase 2 in preparation

 

Sinbaglustat

GBA2/GCS inhibitor

Rare lysosomal storage disorders

Phase 1 complete

 

ACT-1014-6470

C5aR1 antagonist

Immune-mediated disorders

Phase 1

 

ACT-777991

CXCR3 antagonist

Recent-onset Type 1 diabetes

Phase 1

 

IDOR-1117-2520

Undisclosed

Immune-mediated disorders

Phase 1

 

IDOR-1134-2831

Synthetic glycan vaccine

Clostridium difficile infection

Phase 1 in preparation

 

 

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker.

On July 20, 2023, Idorsia sold its operating businesses in the Asia Pacific (ex-China) region to Sosei Heptares, including the assignment of the license for PIVLAZ (clazosentan) for the Asia Pacific (ex-China) region. Idorsia retains the rights to clazosentan in the rest of the world.